Dataset Information

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus.

ABSTRACT:

Introduction

Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues.

Methods

A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1="disagree" and 9="agree").

Results

First-line antipsychotics varied depending on predominant symptoms: risperidone (mean±standard deviation score, 7.9±1.4), olanzapine (7.5±1.6), and aripiprazole (6.9±1.9) were more likely selected for positive symptoms; aripiprazole (7.6±1.6) for negative symptoms; aripiprazole (7.3±1.9), olanzapine (7.2±1.9), and quetiapine (6.9±1.9) for depression and anxiety; and olanzapine (7.9±1.5) and risperidone (7.5±1.5) for excitement and aggression. While only aripiprazole was categorized as a first-line treatment for relapse prevention (7.6±1.0) in patients without noticeable symptoms, aripiprazole (8.0±1.6) and brexpiprazole (6.9±2.3) were categorized as such for social integration. First-line treatments in patients who are vulnerable to extrapyramidal symptoms include quetiapine (7.5±2.0) and aripiprazole (6.9±2.1).

Discussion

These clinical recommendations represent the expert consensus on the use of a particular antipsychotic medication for a particular situation, filling a current gap in the literature.

SUBMITTER: Sakurai H

PROVIDER: S-EPMC7946533 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus.

Sakurai Hitoshi H Yasui-Furukori Norio N Suzuki Takefumi T Uchida Hiroyuki H Baba Hajime H Watanabe Koichiro K Inada Ken K Kikuchi Yuka Sugawara YS Kikuchi Toshiaki T Katsuki Asuka A Kishida Ikuko I Kato Masaki M

Pharmacopsychiatry 20210112 2

<h4>Introduction</h4>Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues.<h4>Methods</h4>A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1="disagree" and 9="agree").<h4>Results</h4>First-line antipsychotics varied depending on predominant symptoms: rispe ...[more]

PMID: 33434943

Similar Datasets

Project description:BackgroundChronic urticaria (CU) is a common disease which represents a considerable burden for many patients. The current urticaria guideline describes the evidence-based diagnosis and treatment of CU. In addition, however, questions often arise in everyday practice that are not addressed by the guideline.MethodsIn May 2020, a digital meeting with German urticaria experts was held, in which practical aspects of CU treatment were discussed and supporting aids for everyday clinical treatment formulated. The resulting advice in this document focus on practical questions and the available literature and experiences of the participants.ResultsThe diagnosis of CU can be made in a short time by means of a thorough anamnesis, a physical examination, and a basic laboratory chemical diagnosis. For this purpose, practical recommendations for everyday practice are given in this paper. An extended diagnosis is only indicated in a few cases and should always be carried out in parallel with an effective therapy. In general, CU should always be treated in the same way, regardless of whether wheals, angioedema or both occur. Symptomatic therapy should be carried out according to the treatment steps recommended by the guidelines. This publication provides practical advice on issues in everyday practice, such as the procedure in the current coronavirus disease 2019 (COVID-19) pandemic, the cardiac risk under higher dosed H1 antihistamines, the self-administration of omalizumab as well as vaccination under omalizumab therapy. In addition to treatment recommendations, topics such as documentation in the practice and family planning with urticaria will be discussed.DiscussionThese supporting treatment recommendations serve as an addendum to the current CU guideline and provide support in dealing with CU patients in everyday practice. The aim is to ensure that patients suffering from CU achieve complete freedom of symptoms with the help of an optimal therapy.Supplementary informationThe online version of this article (10.1007/s40629-021-00162-w) contains supplementary material, which is available to authorized users.

Dataset Information

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus.

Introduction

Methods

Results

Discussion

Publications

Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets